Ll 37 vs Thymosin Alpha 1
Which Is Right for You? Complete Comparison (2026)
LL-37 vs Thymosin Alpha 1 — cathelicidin that kills pathogens directly vs thymic peptide that enhances T-cell and NK cell immunity.
Ll 37 vs Thymosin Alpha 1: At a Glance
- ✓Human cathelicidin antimicrobial peptide (37 amino acids)
- ✓Directly disrupts microbial membranes (bactericidal)
- ✓Modulates innate and adaptive immune responses
- ✓Promotes wound healing and angiogenesis
- ✓Anti-biofilm activity against resistant organisms
- ✓Thymus-derived 28-amino acid immune peptide
- ✓Enhances T-cell maturation and cytokine production
- ✓Activates dendritic cells and NK cells
- ✓FDA orphan drug for hepatitis B; approved in 35+ countries
- ✓Used as immune adjuvant in cancer and chronic infections
Detailed Comparison
| Feature | Ll 37 | Thymosin Alpha 1 |
|---|---|---|
| Mechanism | Cathelicidin antimicrobial peptide | Thymic immune-modulating peptideBest |
| Dosing | 100-200 mcg SC daily or 2-3x weekly | 1.6 mg SC 2x weekly (Zadaxin approved dose) |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Half-life | ~2-4 hours | ~2 hours |
| FDA Status | Not FDA-approved — research peptide | FDA orphan drug status; approved in 35+ countries (Zadaxin) |
| Key Trial | Vandamme D et al. Cell Immunol 2012 — comprehensive review | Garaci E et al. Ann NY Acad Sci 2007 — bench to bedside review |
| Side Effects | Injection site pain/redness, potential mast cell activation at high doses | Very well-tolerated; mild injection site reactions |
Which Should You Choose?
LL-37 (cathelicidin antimicrobial peptide) and Thymosin Alpha-1 (Zadaxin) (thymic immune-modulating peptide) target different aspects of health despite overlapping interest areas. LL-37 human cathelicidin-derived antimicrobial peptide that directly kills bacteria, viruses, and fungi while modulating immune response and promoting wound healing. Thymosin Alpha-1 (Zadaxin) thymus-derived 28-amino acid peptide that enhances t-cell maturation, dendritic cell function, and nk cell activity for broad immune enhancement.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Making an Informed Choice Between Ll 37 and Thymosin Alpha 1
Choosing between Ll 37 and Thymosin Alpha 1 depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between Ll 37 and Thymosin Alpha 1 is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
Ll 37 vs Thymosin Alpha 1: Frequently Asked Questions
LL-37 is a cathelicidin antimicrobial peptide while Thymosin Alpha-1 (Zadaxin) is a thymic immune-modulating peptide. They differ in mechanism, dosing, and clinical evidence. Your choice should depend on your specific goals and medical history.
Switching should be done under medical supervision. Your prescriber can advise on transition protocols. Track both in Shotlee for comparison data.
LL-37 works as a cathelicidin antimicrobial peptide (100-200 mcg SC daily or 2-3x weekly), while Thymosin Alpha-1 (Zadaxin) is a thymic immune-modulating peptide (1.6 mg SC 2x weekly (Zadaxin approved dose)). They have different half-lives (~2-4 hours vs ~2 hours), side effect profiles, and levels of clinical evidence.
Yes. Shotlee supports tracking any medication or peptide. You can compare your results across different protocols.
Neither is universally better — the right choice depends on your individual health profile, treatment goals, side effect tolerance, insurance coverage, and prescriber recommendation. Clinical trial data shows efficacy differences in specific populations, but personal response varies. Track your experience with either medication in Shotlee to generate objective comparison data with your healthcare provider.
Switching between these medications should be done under medical supervision. Your prescriber will consider factors including your current response, reason for switching, dose equivalence, and transition timing. Use Shotlee to document your outcomes on the current medication so you have a clear baseline for comparison after switching.
Track Ll 37 or Thymosin Alpha 1 in Shotlee
Free dose tracking, side effect logging, and outcome comparison for any medication protocol.